Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 10;220(4):e201912060. doi: 10.1083/jcb.201912060

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Chang et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure S3. — RNA mediates the interaction between TORC1 and P-body components under glucose starvation (A) Comparison of promoter strengths. The mRNA expression levels of TOR1 and KOG1 under different promoters were compared. The mRNA levels of TOR1 and KOG1 were normalized against those of ACT1. Numbers indicate fold increases compared with TOR1 and KOG1 expressed from their own promoters. Error bars represent SD. (B) Protein expression levels of Kog1 under different promoters. The relative ratio of Kog1 to hexokinase was calculated, and the mean ± SD of triplicate experiments is shown below each lane. (C–F) Interaction between TORC1 and P-body components. Immunoprecipitation was performed with anti-c-Myc antibody, and coimmunoprecipitated GFP-Kog1 or GFP-Tor1 was detected by Western blotting with anti-GFP antibody. The relative ratio of coimmunoprecipitated Kog1-GFP or Tor1-GFP to input proteins is shown below each lane. (C) Interaction between Kog1 and P-body components under glucose starvation. (D) Interaction between Tor1 and a P-body component Dhh1 in cells with cycloheximide treatment, edc3Δ lsm4ΔC double mutation, or Ego1-conjugated Tor1. For cycloheximide treatment, cells were pretreated with cycloheximide 10 min before glucose starvation. (E) Interaction between Tor1 and a P-body component Pat1 in cells with cycloheximide treatment or Ego1-conjugated Tor1. (F) Interaction between Tor1 and a P-body component Xrn1 in cells with cycloheximide treatment or edc3Δ lsm4ΔC double mutation. (G) Interaction between Tor1 and Gtr1 under glucose starvation or RNase treatment.